Welcome to our dedicated page for Kymera Therapeutics news (Ticker: KYMR), a resource for investors and traders seeking the latest updates and insights on Kymera Therapeutics stock.
Kymera Therapeutics develops targeted protein degradation medicines for immunological diseases as a clinical-stage biopharmaceutical company. News about KYMR commonly centers on oral small molecule degrader programs, including KT-621, a STAT6 degrader for Type 2 inflammatory diseases such as atopic dermatitis and asthma, and KT-579, an IRF5 degrader tied to inflammatory bowel disease biology.
Company updates also cover preclinical and clinical data presentations, FDA regulatory designations, collaboration activity involving degrader candidates such as KT-200, and periodic operating and financial results. Additional announcements include investor conference participation and shareholder voting matters.
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company, announced its participation in several upcoming virtual investor conferences. Notable events include a panel discussion at the UBS conference on November 1, 2021, and fireside chats at the Credit Suisse and Stifel healthcare conferences on November 11 and 15, respectively. Kymera focuses on targeted protein degradation, with its Pegasus™ platform addressing high-impact targets for immune-inflammatory diseases and cancers. For more details, webcasts will be available on their website.
Kymera Therapeutics (NASDAQ: KYMR) announced promising results from its Phase 1 trial of KT-474, a selective IRAK4 degrader. The Single Ascending Dose (SAD) trial showed up to 96% mean reduction of IRAK4 in PBMC within 48 hours, and up to 97% inhibition of pro-inflammatory cytokines. KT-474 was well-tolerated across all dose levels, with no serious adverse events reported. The MAD portion is underway, evaluating daily dosing. Kymera plans to present additional data before year-end, advancing its aim to target immune-inflammatory diseases.
Kymera Therapeutics (NASDAQ: KYMR) announced a conference call and webcast on October 27 to review data from the Single Ascending Dose (SAD) phase of the KT-474 trial. This presentation will feature Dr. Jared Gollob, the Chief Medical Officer, and will begin at 8:30 a.m. ET, followed by the conference call at 10:30 a.m. ET. The event aims to discuss Kymera's advancements in targeted protein degradation therapies, particularly for immune-inflammatory diseases and malignancies, highlighting its innovative Pegasus™ platform.
Kymera Therapeutics (NASDAQ: KYMR) announced multiple presentations at the 4th Annual Targeted Protein Degradation Summit from October 26-29, 2021. Keynote presentations will detail safety, pharmacokinetics (PK), and pharmacodynamics (PD) data from the Single Ascending Dose (SAD) phase of the KT-474 Phase 1 trial in healthy volunteers. KT-474, an orally available IRAK4 degrader, targets immune-inflammatory diseases like rheumatoid arthritis. The company plans to present further data from the Multiple Ascending Dose (MAD) phase by year-end.
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company, announced participation in two upcoming investor conferences. The first is the Morgan Stanley 19th Annual Global Healthcare Conference, featuring a live webcast on September 9, 2021, at 1:15 p.m. ET. The second is the H.C. Wainwright 23rd Annual Global Investment Conference, with an on-demand presentation available from September 13, 2021, at 7:00 a.m. ET. Webcasts can be accessed on the Company's website, where archived versions will be available for 30 days.
Kymera Therapeutics (NASDAQ: KYMR) reported positive interim results from its Phase 1 trial of KT-474, a first-in-class oral IRAK4 degrader, demonstrating a 94% degradation rate. The company initiated dosing for the Multiple Ascending Dose (MAD) portion of the trial and expects Investigational New Drug Applications (IND) for KT-413 and KT-333 in 2H 2021. Following a successful follow-on offering, Kymera now has a pro forma cash position of $647 million to support ongoing development and pipeline expansion. Collaboration revenues rose to $18.5 million while net loss for Q2 2021 was $24.7 million.
Kymera Therapeutics (NASDAQ: KYMR) announced the appointments of Karen Weisbach as Vice President of People and Culture and Jolly Bhatia as Vice President of Quality. Weisbach brings over 15 years of HR experience from bluebird bio, focusing on talent strategies. Bhatia, with 25 years in quality oversight, previously held roles at X4 Pharmaceuticals and Alnylam Pharmaceuticals. These appointments are part of Kymera's effort to strengthen its capabilities in targeted protein degradation and expand its pipeline, which targets immune-inflammatory diseases and various cancers.
Summary not available.
Kymera Therapeutics (NASDAQ: KYMR) has completed an upsized public offering of 5,468,250 shares at a price of $47.00 per share, raising approximately $257.0 million in gross proceeds. The offering includes an additional 713,250 shares from underwriters' options. The funds will support Kymera's mission to develop novel small molecule protein degraders to tackle difficult disease targets. The company is focused on the treatment of immune-inflammatory diseases and certain cancers through its innovative Pegasus™ platform.
Kymera Therapeutics (NASDAQ: KYMR) announced the pricing of its public offering of 4,755,000 shares at $47.00 per share, raising approximately $223.5 million in gross proceeds. All shares are offered by Kymera, with underwriters granted a 30-day option to purchase an additional 713,250 shares. The offering is expected to close on July 6, 2021, pending customary conditions. Morgan Stanley, J.P. Morgan, Cowen, and Guggenheim Securities are acting as joint book-running managers for the offering.